Histological comparison of three apatitic bone substitutes with different carbonate contents in alveolar bone defects in a beagle mandible with simultaneous implant installation by Mano, Takamitsu et al.
1 
Histological comparison of three apatitic bone substitutes with different carbonate 
contents in alveolar bone defects in a beagle mandible with simultaneous implant 
installation 
Takamitsu Mano1, Kazuya Akita1, Naoyuki Fukuda1, Kumiko Kamada1, 
Naito Kurio1, Kunio Ishikawa2, Youji Miyamoto1 
1 Department of Oral Surgery, Institute of Biomedical Sciences, Tokushima University 
Graduate School, 3-18-15 Kuramotocho, Tokushima 770-8504, Japan  
2 Department of Biomaterials, Faculty of Dental Sciences, Kyushu University, 3-1-1 
Maidashi, Higashi-ku, Fukuoka 812-8582, Japan 
Correspondence to: Youji Miyamoto (e-mail: miyamoto@tokushima-u.ac.jp) 
Tel: +81-88-633-7354   Fax: +81-88-633-7462 
This is the peer reviewed version of the following article: Mano, T, Akita, K, Fukuda, N, et al. Histological comparison of three apatitic bone substitutes with 
different carbonate contents in alveolar bone defects in a beagle mandible with simultaneous implant installation. J Biomed Mater Res. 2020; 108: 1450– 1459, 
which has been published in final form at https://doi.org/10.1002/jbm.b.34492. This article may be used for non-commercial purposes in accordance with Wiley 




Since bone apatite is a carbonate apatite containing carbonate in an apatitic 
structure, carbonate content may be one of the factors governing the osteoconductivity 
of apatitic bone substitutes.  The aim of this study was to evaluate the effects of 
carbonate content on the osteoconductivity of apatitic bone substitutes using three 
commercially available bone substitutes for the reconstruction of alveolar bone defects 
of a beagle mandible with simultaneous dental implant installation.  NEOBONE®, 
Bio-Oss®, and Cytrans® that contain 0.1 mass%, 5.5 mass%, and 12.0 mass% of 
carbonate, respectively, were used in this study.  The amount of newly formed bone in 
the upper portion of the alveolar bone defect of the beagle’s mandible was 0.7%, 6.6%, 
and 39.4% at 4 weeks after surgery and 4.7%, 39.5% and 75.2% at 12 weeks after 
surgery for NEOBONE®, Bio-Oss®, and Cytrans®, respectively.  The results indicate 
that bone-to-implant contact ratio was the largest for Cytrans®.  Additionally, the 
continuity of the alveolar ridge was restored in the case of Cytrans®, whereas the 
continuity of the alveolar ridge was not sufficient when using NEOBONE® and 
Bio-Oss®.  Both Cytrans® and Bio-Oss® that has a relatively larger carbonate content 
in their apatitic structure was resorbed with time.  We concluded that carbonate content 
is one of important factors governing the osteoconductivity of apatitic bone substitutes. 
 





Bone is a composite of the inorganic component, carbonate apatite [CO3Ap; 
Ca10−a(PO4)6−b(CO3)c] and the organic components including collagen.
1  Interestingly, 
up to now less attention has been paid to the effect of the carbonate content in an 
apatitic structure of the commercially available bone substitutes on osteoconductivity or 
on the replacement of new bone. 
Although autografts are the gold standard for the reconstruction of bone defects 
due to their osteoinductive, osteoconductive, and osteogenic properties, additional 
surgery is required for harvesting bone, and the low availability of bone as well as the 
complications caused by donor-site morbidity are serious drawbacks.2  Allografts and 
xenografts may be potential alternatives to autografts.  Since the drawbacks of these 
grafts such as immunogenic rejection, and the risk of disease transmission by viruses 
and prions are caused by the organic components, they are removed via thermal 
treatment before their use.  Even though the organic components are removed by 
thermal treatment, the inorganic component of bone, i.e., carbonate apatite, is also 
partially degraded due to their limited stability.  In other words, carbonate apatite 
begins to decompose and release CO2 at temperatures as low as 400°C.
3, 4  Therefore, 
the carbonate content of clinically available xenografts is lower when compared to the 
original bone. 
Other alternatives for bone reconstruction are fully synthetic bone substitutes.5-12  
Among these, sintered hydroxyapatite [HAp; Ca10(PO4)6(OH)2] developed in the 1970s, 
represents a typical fully synthetic bone substitute.  Sintered HAp is a pure ceramic 
and exhibits excellent tissue response and good osteoconductivity.13, 14  Since sintered 
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HAp contains no organic components, immunogenic rejection and disease transmission 
do not occur.  If sintered HAp shows a behavior similar to that of autografts, 
allografts, or xenografts, it could be used exclusively for bone reconstruction surgery.  
However, there are clear differences between the behaviors of autografts and sintered 
HAp.  Although sintered HAp shows osteoconductivity, the degree of 
osteoconductivity is limited when compared to autografts.  Autografts are replaced 
with new bone, whereas sintered HAp is not replaced by bone.13, 14  Aside from the 
organic components and the growth factors contained in the organic components, HAp 
does not contain carbonate in its apatitic structure even though both CO3Ap and HAp 
are classified as apatites. 
Since bone apatite is the CO3Ap, synthetic CO3Ap is expected to exhibit properties 
similar to those of autogenous bone.  Doi et al.15 fabricated sintered CO3Ap with 5.8 
mass% CO3 by sintering at 750°C using CO3Ap powder with high proportions of CO3.  
Unfortunately, thermal decomposition or the loss of carbonate is unavoidable.  
Moreover, the mechanical strength of the sintered CO3Ap is low due to the low 
sintering temperature. 
Recently, CO3Ap block was fabricated in an aqueous solution by a 
dissolution-precipitation reaction using precursor blocks.16-19  The CO3Ap block 
contained a larger amount of CO3 in the apatitic structure and its crystallinity was 
closer to that of autogenous bone when compared to sintered CO3Ap or sintered HAp.  
The CO3Ap block fabricated in an aqueous solution upregulated osteoblastic 
differentiation of human bone marrow cells, and was resorbed by osteoclasts.16, 20-22  
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Fujisawa et al.23 reported that the CO3Ap showed faster bone formation especially in 
the cortical bone portion than Bio-Oss®, a bovine-derived xenograft, at 8 weeks after 
implantation in the bone defect of a rabbit femur.  These results clearly demonstrated 
the potential value of the CO3Ap block as an alternative to autografts.  The CO3Ap 
block is now commercially available as Cytrans®. 
The objective of this study was, therefore, to evaluate the osteoconductivity of three 
apatitic bone substitutes with different carbonate contents; a fully synthetic CO3Ap 
fabricated in an aqueous solution (Cytrans®), a bovine-derived xenograft (Bio-Oss®), 
and a fully synthetic HAp (NEOBONE®).  Simultaneous installation of an implant in 
an alveolar bone defect of a beagle dog mandible was performed. 
 
MATERIALS AND METHODS 
The three apatitic bone substitute granules 
NEOBONE® (Coorstec, Tokyo, Japan), Bio-Oss® (Geistlich Pharma AG, Wolhusen, 
Switzerland), and Cytrans® (GC Corporation, Tokyo, Japan) were used as apatitic bone 
substitutes.  
NEOBONE® is a pure HAp porous granule fabricated by the sintering method.  
The NEOBONE ® granules were 500 - 1000 μm in diameter.  Bio-Oss® is a widely 
used bovine-derived xenograft.  Bovine bone is treated to eliminate the organic 
components.  The Bio-Oss® granules were 250 - 1000 μm in diameter.  Cytrans® is a 
pure CO3Ap dense granule fabricated in an aqueous solution through a dissolution–
precipitation reaction using Ca(OH)2 granules as precursors.
16-19, 24  The CO3Ap 
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granules were 300 - 600 μm in diameter. 
Scanning electron microscopic observations 
The morphology of the bone substitutes was analyzed by a scanning electron 
microscope (SEM) (JCM-5700, JEOL Ltd., Tokyo, Japan) under an accelerating voltage 
of 15 kV after coating with gold palladium using a magnetron sputtering machine (IB-3, 
EIKO Corporation, Tokyo, Japan). 
Compositional analysis 
The compositions of the bone substitutes were analyzed using a powder X-ray 
diffractometer (XRD), Fourier Transformed Infrared (FT-IR) Spectrometer.  CO3 
content was calculated based on a C content measured using a CHN coder.  For the 
XRD analysis, the samples were ground to fine powders, and the XRD patterns were 
recorded using a diffractometer (XRD; SmartLab, Rigaku Corporation, Tokyo, Japan) 
using CuKα radiation generated at 40 kV and 40 mA.  The samples were scanned from 
a 2θ of 10° to 40° (where θ is the Bragg angle) in a continuous mode.  Crystallite sizes 
were calculated from the XRD pattern using Scherrer’s equation.  For the FT-IR 
analysis, the FT-IR spectra were measured by a KBr disc method using a spectrometer 
(FT/IR-6200, JASCO Corporation, Tokyo, Japan).  A CHN coder (MT-6; Yanako 
Analytical Instruments, Kyoto, Japan) was used to analyze the carbon content.  Then, 
the carbonate contents were calculated from the carbon content as follows. 







Porosity of the bone substitutes was evaluated by 
Porosity (%)  =  
Vp
Vp + Vs
 × 100 
where Vp and Vs are the pore volume and the volume of the samples, respectively.  The 
pore volume of the bone substitutes was measured by a specific surface area analyzer 
(BELSORP-mini II, MicrotracBEL, Osaka, Japan).  The volume of the samples was 
measured by pycnometer method, where ethanol was used as the immersion liquid. 
Dissolution rate evaluation 
The dissolution rate of the three bone substitutes was measured according to 
Japanese Industrial Standards T0330-3.  In brief, the three bone substitutes were 
immersing in 0.08 mol/L pH 5.5 acetic acid-sodium acetate solution (100 mL), and 0.05 
mol/L pH 7.3 tris (hydroxymethyl) aminomethane-HCl buffer solution (100 mL) at 25 ± 
3°C.  Sample (100 ± 1 mg) was lifted in the solution using a thread with continuous 
stirring.  After 30 minutes, the Ca2+ concentration in the solution was measured using a 
Ca ion electrode (6583-10C, Horiba, Ltd., Kyoto, Japan) as an index of dissolution rate 
(n = 3). 
Animal experiments 
Six male beagle dogs (weight: 8 - 11 kg) were obtained from commercial sources 
(Kitayama Rabesu, Nagano, Japan) and housed in the animal unit (Hamri Co., Ltd., 
Ibaraki, Japan) in a controlled environment.  The experimental protocol was approved 
by the Institutional Animal Care and Use Committee (IACUC) of Hamri Co., Ltd.; 
IACUC approval number-No. 15-H066.  The animals housed in individual cages 
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were provided with water and specific pellet-type laboratory animal food. 
The animals were anesthetized with ketamine (10 mg/kg) and xylazine (3 mg/kg) 
via intramuscular injection.  After local anesthesia was induced by administering 2% 
lidocaine containing 1:80,000 epinephrine, all mandibular premolars (first, second, 
third and fourth premolars) were extracted.  After eight weeks of healing, 
mucoperiosteal flaps were elevated and bone defects 7 mm in length, 2 mm in width 
and 6 mm in depth were created by a fissure bur (Morita Co., Ltd., Suita, Japan) with 
irrigation using normal saline solution (Fig. 1a).  A titanium screw type implant that 
was 6 mm in length and 2.2 mm in diameter was installed into the distal end of the 
bone defects (Fig. 1b).  Thereafter, three types of bone substitutes (NEOBONE®, 
Bio-Oss®, and Cytrans®) were used to fill in the residual bone defects (n=3) (Fig. 1c).  
The surgical wound was closed with 4-0 nylon sutures.  After the operation, injection 
of enrofloxacin (Baytril®, Bayer Medical Co., Ltd., Leverkusen, Germany) (0.4 
mL/kg/10 mg) was administered intramuscularly once a day for 3 days to prevent 
infections and buprenorphine (20 µg/0.1 mL/kg) (Lepetan®, Otsuka Pharmaceutical 
Co., Ltd., Tokushima, Japan) was administered for pain relief subcutaneously to the 
animals once a day for 4 days.  The operative sites were disinfected with 
povidone-iodine (Isodine®, Meiji Seika Pharma Co., Ltd., Tokyo, Japan) once a day.  
The sutures were removed 2 weeks after the operation. 
Histological analysis 
After 4 and 12 weeks of implantation, the animals were sacrificed using a lethal 
dose of intravenous pentobarbital (over 50 mg/kg).  The samples along with the 
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surrounding tissue were carefully harvested from the mandibular bone and fixed in 10% 
buffered formalin for 3 days, and then dehydrated by immersion in a 70% to 100% 
ethanol gradient with immersion in each grade for 3 days.  Finally, the samples with 
the surrounding tissue were embedded in methyl methacrylate.  Then, undecalcified 
sections were prepared for histological analysis using a modified interlocked diamond 
saw (Exakt, Hamburg, Germany).  Subsequently, Villanueva Goldner stain was 
applied to all sections and observed using a light microscope (BX43, OLYMPUS, 
Tokyo, Japan).  The newly formed area of bone in the whole defect was measured 
using the software Image J (US National Institutes of Health, Bethesda, MD, USA).  
Next, the whole defect was divided into two portions (the upper portion and the lower 
portion) and the newly formed bone area in each portion was measured in the same 
manner.  Bone-to-implant contact ratio was also measured using Image J as an index 
of osteoconductivity.  Briefly, the percentage of surface length of the implant that was 
in direct contact with the bone was calculated.  To observe the change in granule size, 
the areas of Bio-Oss® and Cytrans® granules in all sections were measured using Image 
J, and the mean areas of the Bio-Oss® and Cytrans® granules were calculated as a 
measure of granule size.  The granule size of NEOBONE® could not be measured, 
because NEOBONE® has a lot of pores that form bubble-like clusters. 
Statistical analysis 
A one-way factorial ANOVA and Fisher’s least significant difference post-hoc test 
were performed using Kaleida Graph 4 (Synergy Software Solutons Inc., PA, USA).  






Morphologic and compositional analysis  
Figure 2 shows SEM images of NEOBONE® (a, d), Bio-Oss® (b, e), and Cytrans® 
(c, f).  As shown, the structure of these three bone substitutes was different.  
NEOBONE® showed a typical porous structure fabricated using a spherical porogen 
(Fig. 2a).  Higher magnification revealed the smooth surface typical of high 
temperature sintered ceramics (Fig. 2d). 
Bio-Oss® had pores, as claimed by the manufacturer.  However, as shown in Fig. 
2b, the number of pores was limited when compared to those in NEOBONE®.  Higher 
magnification revealed interwinded bundle-like structures (Fig. 2e). 
In contrast to NEOBONE® and Bio-Oss®, Cytrans® was composed of dense 
granules (Fig. 2c).  Higher magnification revealed aggregation of small crystals (Fig. 
2f).  In other words, the small crystals were interlocked.  This structure is typical for 
products made via a dissolutionprecipitation reaction such as gypsum. 
Figure 3 shows the XRD patterns of NEOBONE®, Bio-Oss®, and Cytrans®.  All 
bone substitutes demonstrated only apatitic patterns, indicating that they did not contain 
any other crystalline structures.  For NEOBONE®, the XRD peaks were sharp 
indicating high crystallinity.  This is typical for ceramics sintered at high temperature.  
In contrast, Bio-Oss® and Cytrans® demonstrated broad peaks indicating low 
crystallinity.   
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Figure 4 shows the FT-IR spectra of NEOBONE®, Bio-Oss®, and Cytrans®.  
Similar to XRD analysis, the FT-IR spectra also demonstrated apatitic spectra for all 
bone substitutes.  In the case of NEOBONE®, the peak attributed to OH was observed 
at 638 cm−1 (△) and no peaks attributed to carbonate were observed, indicating that 
NEOBONE® is a hydroxyapatite.  In contrast, no absorption peak attributed to OH was 
observed at 638 cm−1 for both Bio-Oss® and Cytrans®.  Instead, absorption peaks at 
1474, 1418 and 875 cm−1 (▲), indicating that both Bio-Oss® and Cytrans® are AB-type 
CO3Ap, or CO3Ap in which both A site or OH site, and B site or PO4 site are replaced 
with CO3.  The absorption peaks were larger for Cytrans
® when compared with 
Bio-Oss®, indicating that the carbonate content in apatite is larger in Cytrans® compared 
to Bio-Oss®. 
Table 1 summarizes the chemical and physical properties of NEOBONE®, 
Bio-Oss®, and Cytrans®.  Carbonate content is highest for Cytrans® followed by 
Bio-Oss® and NEOBONE®.  Crystallite size is highest for NEOBONE® followed by 
Cytrans® and Bio-Oss®.  Porosity of Bio-Oss® is more than twice larger than that of 
Cytrans®. 
Dissolution rate evaluation 
Figure 5 shows the results of dissolution rate evaluation.  At pH 7.3 that 
mimicking physiological condition, all bone substitutes show limited dissolution rate 
even though Bio-Oss® and Cytrans® showed larger dissolution rate than NEOBONE® 
(Fig 5a).  At pH 5.5 that mimicking inside a Howship's lacuna condition produced by 
osteoclasts, dissolution rate increased significantly when compared to the results of pH 
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7.3 regardless of the type of bone substitute.  Among the bone substitutes, both 
Bio-Oss® and Cytrans® showed larger dissolution rate (Fig 5b). 
Figure 6 shows the results of dissolution rate standardized by specific surface area.  
At pH 7.3, both Bio-Oss® and Cytrans® showed limited dissolution rate.  At pH 5.5, 
Cytrans® showed statistically significant (p < 0.01) larger dissolution rate than that of 
Bio-Oss®. 
Histological analysis 
Figure 7 shows Villanueva Goldner staining in histological images of NEOBONE® 
(a, d), Bio-Oss® (b, e) and Cytrans® (c, f) at 4 weeks after implantation.  In the case of 
NEOBONE®, new bone formation was observed only in the lower portion of the bone 
defect (Fig. 7a).  Larger amounts of new bone were observed for Bio-Oss® when 
compared to NEOBONE®.  New bone extended from the existing bone.  However, 
little bone was formed in the central portion (Fig. 7b).  The largest amount of new 
bone was observed when the defect was reconstructed with Cytrans®.  Additionally, 
new bone formation was observed even in the central and upper portions (Fig. 7c).  
High magnification imaging revealed that new bone was not formed around the 
NEOBONE® granules in the central portion, and that infiltration of some lymphocytes 
was observed (Fig. 7d).  In contrast, new bone was observed at the periphery of some 
of the granules in the case of Bio-Oss® (Fig. 7e).  It should be noted that most of the 
Cytrans® granules were covered with new bone or osteoid (red) (Fig. 7f).  Infiltration 
of few inflammatory cells and foreign body giant cells was observed in cases of 
Bio-Oss® and Cytrans®. 
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Figure 8 shows Villanueva Goldner staining in histological images of NEOBONE® 
(a, d), Bio-Oss® (b, e) and Cytrans® (c, f) at 12 weeks after implantation.  The amount 
of the new bone increased when compared to 4 weeks regardless of the type of apatitic 
bone substitute.  In the case of NEOBONE®, trabecular bone was not observed even 
though pores were filled with newly formed bone in the lower portion of the bone defect 
(Fig. 8a).  At high magnification, lymphocyte infiltration decreased when compared to 
4 weeks.  Small amounts of new bone were observed even in the central area of the 
bone defect (Fig 8d).  In the case of Bio-Oss®, larger amounts of new bone were 
observed in the central area when compared to NEOBONE®.  However, the continuity 
of the alveolar ridge was not restored (Fig. 8b).  At high magnification, some Bio-Oss® 
granules covered with new bone were observed (Fig. 8e).  In the case of Cytrans®, new 
bone was formed uniformly all over the bone defect and the continuity of the alveolar 
ridge was restored (Fig. 8c).  The new bone was in direct contact with the granules 
without the presence of an intermediate layer of fibrous tissue and most of the granules 
were covered with new bone (Fig. 8f).  The osteoid was gradually replaced with 
mature bone and cuboidal osteoblasts indicating activated osteoblasts, were present on 
the surface of the osteoid.  The size of the Bio-Oss® and Cytrans® granules at 12 
weeks was smaller than that at 4 weeks. 
Figure 9 shows the percentage of new bone in the whole bone defect.  The 
percentages of new bone in NEOBONE®, Bio-Oss® and Cytrans® at 4 weeks after 
implantation were 6.5 ± 3.3%, 17.9 ± 4.2% and 42.2 ± 19.4%, respectively.  The area 
of new bone was significantly larger for Cytrans® and Bio-Oss® than in NEOBONE®.  
14 
 
The percentage of new bone in NEOBONE®, Bio-Oss® and Cytrans® at 12 weeks after 
implantation were 25.7 ± 6.0%, 41.5 ± 1.9% and 61.9 ± 5.3%, respectively.  The area 
of new bone increased at 12 weeks when compared to 4 weeks regardless of the type of 
bone substitute.  Moreover, the order of the amount of new bone was the same as that 
observed at 4 weeks.  Significantly larger amounts of new bone were observed for 
Cytrans® when compared to NEOBONE® and Bio-Oss®. 
Figure 10 shows the percentage of the new bone areas in the upper portion (alveolar 
ridge portion; 10a) and in the lower portion (bone marrow portion; 10b), at 4 and 12 
weeks after implantation.  The trend shown by the formation of new bone was the 
same as that shown in Figure 9.  However, the differences in the new bone formation 
area based on the type of bone substitute were much more significant in the upper 
portion.  In the upper portion, the areas of new bone formation for NEOBONE®, 
Bio-Oss® and Cytrans® at 4 and 12 weeks after implantation were 0.7 ± 0.3%, 6.6 ± 
7.2%, 39.4 ± 15.0% and 4.7 ± 4.9%, 39.5 ± 26.9% and 75.2 ± 5.7%, respectively.  In 
the lower portion, the areas of new bone formation for NEOBONE®, Bio-Oss®, and 
Cytrans® at 4 and 12 weeks after implantation were 12.0 ± 6.5%, 28.9 ± 4.9%, and 45.6 
± 26.9%, and 46.1 ± 14.2%, 45.4 ± 29.4%, and 51.5 ± 9.2%, respectively. 
Figure 11 shows the histological images of the titanium implant surface when 
implanted adjacent to the bone defect filled with NEOBONE® (a, d), Bio-Oss® (b, e) 
and Cytrans® (c, f) for 4 weeks (a - c) and 12 weeks (d - f).  At 4 weeks, in the case of 
NEOBONE®, the titanium implant was barely in contact with the new bone (Fig. 11a).  
In the case of Bio-Oss® (Fig. 11b) and Cytrans® (Fig. 11c), the titanium implant was in 
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direct contact with the new bone.  At 12 weeks, the bone-to-implant contact area 
increased when compared to 4 weeks regardless of the type of bone substitute.  In the 
case of NEOBONE® and Bio-Oss®, the titanium implant was in partial contact with the 
new bone (Fig. 11d, e).  In contrast, for Cytrans®, most of the titanium implant surface 
was covered with the new bone (Fig. 11f). 
Figure 12 shows the percentage of the bone-to-implant contact ratio.  The contact 
ratios of NEOBONE®, Bio-Oss® and Cytrans® were 2.2 ± 2.1%, 13.4 ± 5.4%, 19.4 ± 
12.4%, and 36.6 ± 6.9%, 37.2 ± 10.8%, 62.3 ± 8.0%, after 4 and 12 weeks, respectively.  
The bone-to-implant contact ratios increased with time regardless of the bone substitute 
used to fill the adjacent bone defect.  Cytrans® showed a significantly higher 
bone-to-implant contact ratio than NEOBONE® and Bio-Oss® at 12 weeks. 
Figure 13 summarizes the resorption of the Bio-Oss® and Cytrans® granules using 
granule area as an index.  The mean area of Bio-Oss® was 0.103 ± 0.064 mm2, 0.073 ± 
0.072 mm2 and 0.065 ± 0.076 mm2 at 0, 4 and 12 weeks, respectively.  In addition, the 
mean area of the Cytrans® granules was 0.091 ± 0.057 mm2, 0.074 ± 0.058 mm2, and 
0.054 ± 0.040 mm2 at 0, 4, and 12 weeks, respectively.  Both Bio-Oss® and Cytrans® 
granules were gradually resorbed with time even though statistically significant 
differences were not recognized. 
 
DISCUSSION 
Results obtained in this study clearly demonstrated the usefulness of CO3Ap bone 
substitute with larger CO3 content in apatitic structure.  As well known, new bone is 
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formed from the existing bone and/or the periosteum.  Osteoblasts in existing bone 
and/or periosteum are upregulated thus forming greater amounts of bone.  In other 
words, Cytrans® that contains 12.0 ± 0.6 mass% CO3 showed the highest rate of bone 
formation among the three apatitic bone substitutes.  The bone formation rate followed 
by Bio-Oss® that contains 5.5 ± 0.2 mass% CO3, and NEOBONE
® that contains 0.1 ± 
0.1 mass% CO3.  Clearest difference on the new bone formation was observed in the 
upper portion of the alveolar bone defect.  For Cytrans®, new bone formation derived 
from the periosteum is observed in the upper portion of the alveolar bone defect.  It 
should be noted that the upper portion of the alveolar bone defect is the last part derived 
from the existing bone. 
As a results of greater amount of new bone formation, higher bone-to-implant 
contact ratio was observed when the adjacent bone defect was filled with Cytrans® (Figs. 
11,12).  The newly formed bone bonded to the titanium implant because of titanium’s 
osteointegration ability.  
These results are not only fruitful to patients but also allow great chance to 
understand factors to determine the osteoconductivity.  Obviously, CO3 content in 
apatitic structure and the percentage of new bone in the whole bone defect correlate 
well.  The formers are 0.1 ± 0.1 mass%, 5.5 ± 0.2 mass%, 12.6 ± 0.6 mass%, and the 
latters are 6.5 ± 3.3%, 17.9 ± 4.2%, 42.2 ± 19.4% in 4 weeks and 25.7 ± 6.0%, 41.5 ± 
1.9% and 61.9 ± 5.3% in 12 weeks for NEOBONE®, Bio-Oss® and Cytrans®, 
respectively.  The results are consistent with the previous results.  Germaini et al.25 
reported that 4.4 wt% carbonate substituted hydroxyapatite promoted a significantly 
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higher level of pre-osteoblast proliferation than HAp containing no CO3 in apatitic 
structures.  Nagai et al.20 also reported that CO3Ap upregulated the osteoblastic 
differentiation of cultured human bone marrow cells when compared to HAp. 
One of the causes of the higher osteoconductivity for bone substitutes with larger 
CO3 content in apatitic structure may be larger solubility at the weak acidic condition 
produced by osteoclasts, and resulting upregulation of osteoblasts by Ca2+.  It is well 
known that the solubility of apatite in weak acidic conditions increases with CO3 
content in apatitic structures.26  Therefore, osteoclastic resorption increases with CO3 
content in apatitic structures because Howship’s lacuna produced by osteoclasts 
represents a weak acidic environment.  In fact, Spence et al.21 reported that higher 
carbonate content led to an increased osteoclastogenesis and allowed resorption of the 
substitute in a dose dependent manner in vivo.  Further, Fujisawa et al.23 reported that 
the size of the CO3Ap granules became smaller with implantation time in vivo.  The 
resorption of bone or dissolution of apatite elevates Ca2+ concentration since both bone 
and apatite are composed of calcium-phosphate.  Lee et al.27 reported that elevated 
extracellular Ca2+ enhanced osteoblastic differentiation in cultured murine osteoblasts, 
including the expression and secretion of osteopontin and matrix mineralization.  
Maeno et al.28 also demonstrated that a Ca2+ concentration of about 5 mM, which is 
higher than the physiological concentration (2.1 - 2.5 mM in human serum), is 
appropriate for proliferation and differentiation of cultured mouse osteoblasts.  
Therefore, elevated Ca2+ supplied by the resorption of bone or dissolution of apatite 
may be one of key factors for new bone formation, and CO3 content in apatitic 
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structures may be one of keys for new bone formation. 
Although histological comparison of the commercially available bone substitutes is 
important, there are dissimilarities other than CO3 contents.  Obviously, porous 
structure is one of the factors to determine the function of bone substitute.  As shown 
in Fig. 2, NEOBONE® is porous whereas Cytrans® is dense.  Since Cytrans® shows 
much higher osteoconductivity than NEOBONE®, compositional factor seems more 
important than porous structure.  NEOBONE®, a porous HAp containing 0.1 ± 0.1 
mass% CO3 in its apatitic structures, showed limited dissolution rate at pH 5.5 (Fig. 5), 
and was not resorbed at the site of bone defect.  Therefore, Ca2+ elevation at the bone 
defect is limited leading the lowest osteoconductivity. 
Comparison of the Cytrans® and Bio-Oss® is more complex.  CO3 content of 
Cytrans® and Bio-Oss® are 12.0 ± 0.6 mass% and 5.5 ± 0.2 mass%, respectively.  
When dissolution rate is standardized by specific surface area, dissolution rate of 
Cytrans® is larger than that of Bio-Oss® as shown in Fig. 6.  However, dissolution 
rates at pH 5.5 solution without standardization by specific surface area are the same as 
shown in Fig. 5.  Therefore, osteoclastic resorption may be the same and resulting Ca2+ 
elevation and upregulation of osteoblasts may be the same.  There are other 
dissimilarities including the crystallite size, surface morphology and method of 
fabrication.  They may be factors to determine the osteoconductivity.  CO3 content in 
apatitic structure may directly influence the osteoconductivity.  In fact, papers of 
Germaini et al.25 and Nagai et al.20 reported upregulation of proliferation and 
differentiation by CO3Ap than HAp, detailed mechanism of upregulation was not 
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clarified.  Further factor analysis on osteoconductivity is awaited based on the results 
obtained in this study. 
 
CONCLUSION 
In summary, Cytrans® granules that are fabricated in an aqueous solution and have 
the largest CO3 content exhibited the highest rate of bone formation and the highest 
bone-to-implant contact ratio in the alveolar bone defect of a dog mandible with 
simultaneous implant installation when compared to NEOBONE® and Bio-Oss®.  The 
results obtained in this study suggest that CO3 content may be one of the factors 
governing bone formation and resorption in bone defects. 
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FIGURE 1.  Surgical procedures for the creation of the bone defect, installation of the 
implant, and filling of the bone substitutes in the alveolar bone defect. 
Eight weeks after extraction of the premolars, bone defects of 7 mm in length, 2 
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mm in width, and 6 mm in depth were created by using a fissure bur at the premolar 
region (a), screw type titanium implants were installed into the distal end of each 
bone defect (b), each of the bone substitutes was placed in the residual bone defect 
(c). 
 
FIGURE 2.  Scanning electron micrograph images of NEOBONE® (a), Bio-Oss® (b) 
and Cytrans® (c) at low magnification, and high magnification of NEOBONE® (d), 
Bio-Oss® (e), and Cytrans® (f) 
 
FIGURE 3.  X-ray diffraction patterns of NEOBONE® (a), Bio-Oss® (b) and Cytrans® 
(c) 
Black circles indicate the peaks of the HAp. 
 
FIGURE 4.  FT-IR spectrum of NEOBONE® (a), Bio-Oss® (b) and Cytrans® (c) 
Black triangles (▲) indicate the peaks attributed to CO3.  White triangle (△) 
indicate the peak attributed to OH. 
 
FIGURE 5.  Dissolution rates of NEOBONE®, Bio-Oss® and Cytrans® in pH 7.3 




FIGURE 6.  Dissolution rates of NEOBONE®, Bio-Oss® and Cytrans® standardized by 
specific surface area in pH 7.3 buffer solution (a) and in pH 5.5 buffer solution (b).  
**p < 0.01 
 
FIGURE 7.  Histological views of the graft areas of NEOBONE® (a, d), Bio-Oss® (b, 
e) and Cytrans® (c, f) at 4 weeks after implantation (Villanueva Goldner stain).  
Newly formed bone (NB) was stained green, and the osteoid was stained red.  
Asterisks indicate Bio-Oss® and Cytrans® granules. 
 
FIGURE 8.  Histological views of the graft areas of NEOBONE® (a, d), Bio-Oss® (b, 
e) and Cytrans® (c, f) at 12 weeks after implantation.  Arrowheads indicate 
osteoblasts observed on the surface of the osteoid. 
 
FIGURE 9.  Percentage of new bone area in the whole area of the bone defect at 4 and 
12 weeks after implantation.  *p < 0.05, **p < 0.01 
 
FIGURE 10.  Percentage of new bone area in the upper portion (a) and lower portion 




FIGURE 11.  Histological views of the titanium implant surface adjacent to bone 
defect filled with NEOBONE® (a, d), Bio-Oss® (b, e) and Cytrans® (c, f) at 4, and 
12 weeks after implantation.   
 
FIGURE 12.  Bone-to-implant contact ratio of titanium implant adjacent to bone defect 
filled with NEOBONE®, Bio-Oss®  and Cytrans® at 4, and 12 weeks after 
implantation.  **p < 0.01 
 
FIGURE 13.  Mean area of granules at the bone defect filled with Bio-Oss® and 
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Table 1 Chemical and physical properties of NEOBONE®, Bio-Oss® and Cytrans® 






NEOBONE® Synthetic  0.1 ± 0.1 76.3 ± 1.3 not determined 
Bio-Oss® Xenograft  5.5 ± 0.2 18.3 ± 1.3 57.0 ± 0.5 





(a) NEOBONE (b) Bio-Oss
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